Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer

Molecular Carcinogenesis

Volumn 50, Issue 11, 2011, Pages 884-900

  Foreman, Jennifer E ^a   Chang, Wen Chi L ^b   Palkar, Prajakta S ^a   Zhu, Bokai ^a   Borland, Michael G ^a   Williams, Jennie L ^c   Kramer, Lance R ^a   Clapper, Margie L ^b   Gonzalez, Frank J ^d   Peters, Jeffrey M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Clonogenicity; Tumorigenicity

Indexed keywords

[4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; CYCLIN D1; HYDROGEN PEROXIDE; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROTEIN 14 3 3; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CLONOGENESIS; COLON ADENOCARCINOMA; COLON CANCER; COLON TUMOR; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN PEROXIDE; MALE; MICE; MICE, INBRED C57BL; PPAR DELTA; PPAR-BETA;

MUS;

EID: 80054773443     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20757     Document Type: Article

References (51)

1. Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, Peters JM. The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation. Cell Signal 2006; 18: 9-20.
2. Peters JM, Gonzalez FJ. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in cell proliferation and cancer. Biochim Biophys Acta 2009; 1796: 230-241.
3. Peters JM, Hollingshead HE, Gonzalez FJ. Role of peroxisome-proliferator-activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clin Sci (Lond) 2008; 115: 107-127.
4. Berglund L, Bjorling E, Oksvold P, et al. A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics 2008; 7: 2019-2027.
5. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. Rat PPARs: Quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001; 142: 4195-4202.
6. Girroir EE, Hollingshead HE, He P, Zhu B, Perdew GH, Peters JM. Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice. Biochem Biophys Res Commun 2008; 371: 456-461.
7. Kliewer SA, Forman BM, Blumberg B, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994; 91: 7355-7359.
8. Uhlen M, Bjorling E, Agaton C, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005; 4: 1920-1932.
9. Kilgore KS, Billin AN. PPARβ/δ ligands as modulators of the inflammatory response. Curr Opin Investig Drugs 2008; 9: 463-469.
10. Briand F, Naik SU, Fuki I, et al. Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Clin Transl Sci 2009; 2: 127-133.
11. Leibowitz MD, Fievet C, Hennuyer N, et al. Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett 2000; 473: 333-336.
12. Oliver WR, Jr., Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001; 98: 5306-5311.
13. Sprecher DL, Massien C, Pearce G, et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. Arterioscler Thromb Vasc Biol 2007; 27: 359-365.
14. Narkar VA, Downes M, Yu RT, et al. AMPK and PPARδ agonists are exercise mimetics. Cell 2008; 134: 405-415.
15. Grimaldi PA. Metabolic and nonmetabolic regulatory functions of peroxisome proliferator-activated receptor β. Curr Opin Lipidol 2010; 21: 186-191.
16. Lee CH, Olson P, Evans RM. Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003; 144: 2201-2207.
17. Lee CH, Olson P, Hevener A, et al. PPARδ regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 2006; 103: 3444-3449.
18. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335-345.
19. Foreman JE, Sorg JM, McGinnis KS, et al. Regulation of peroxisome proliferator-activated receptor-β/δ by the APC/β-CATENIN pathway and nonsteroidal antiinflammatory drugs. Mol Carcinog 2009; 48: 942-952.
20. Liou JY, Ghelani D, Yeh S, Wu KK. Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3ε. Cancer Res 2007; 67: 3185-3191.
21. Liou JY, Lee S, Ghelani D, Matijevic-Aleksic N, Wu KK. Protection of endothelial survival by peroxisome proliferator-activated receptor-δ mediated14-3-3 upregulation. Arterioscler Thromb Vasc Biol 2006; 26: 1481-1487.
22. Liou JY, Wu CC, Chen BR, Yen LB, Wu KK. Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor-δ transcriptional pathway. Mol Pharmacol 2008; 74: 1399-1406.
23. Wu KK, Liou JY. Cyclooxygenase inhibitors induce colon cancer cell apoptosis via PPARδ→14-3-3ε pathway. Methods Mol Biol (Clifton, NJ) 2009; 512: 295-307.
24. Cooper HS, Chang WC, Coudry R, et al. Generation of a unique strain of multiple intestinal neoplasia (Apc(+/Min-FCCC)) mice with significantly increased numbers of colorectal adenomas. Mol Carcinog 2005; 44: 31-41.
25. Hollingshead HE, Killins RL, Borland MG, et al. Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis 2007; 28: 2641-2649.
26. Ferris FL III, Miller KM, Glassman AR, Beck RW. A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research. Ophthalmology 2010; 117: 1512-1516.
27. Murie C, Woody O, Lee AY, Nadon R. Comparison of small n statistical tests of differential expression applied to microarrays. BMC Bioinform 2009; 10: 45.
28. Rodbard D. A semilogarithmic scale for glucose provides a balanced view of hyperglycemia and hypoglycemia. J Diabetes Sci Technol 2009; 3: 1395-1401.
29. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780-3792.
30. Foreman JE, Sharma AK, Amin S, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits cell growth in a mouse mammary gland cancer cell line. Cancer Lett 2010; 288: 219-225.
31. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protocols 2006; 1: 2315-2319.
32. Chang WC, Everley LC, Pfeiffer GR II, Cooper HS, Barusevicius A, Clapper ML. Sulindac sulfone is most effective in modulating β-catenin-mediated transcription in cells with mutant APC. Ann NY Acad Sci 2005; 1059: 41-55.
33. Shureiqi I, Jiang W, Zuo X, et al. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-δ to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci USA 2003; 100: 9968-9973.
34. Ouyang N, Williams JL, Rigas B. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)δ expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARδ in carcinogenesis. Carcinogenesis 2006; 27: 232-239.
35. Yoshinaga M, Taki K, Somada S, et al. The expression of both peroxisome proliferator-activated receptor delta and cyclooxygenase-2 in tissues is associated with poor prognosis in colorectal cancer patients. Dig Dis Sci 2010; DOI: 10.1007/s10620-010-1389-9.
36. Su W, Necela BM, Fujiwara K, et al. The high affinity peroxisome proliferator-activated receptor-γ agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice. Int J Cancer 2008; 123: 991-997.
37. Niho N, Takahashi M, Shoji Y, et al. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPARγ ligand. Cancer Sci 2003; 94: 960-964.
38. Osawa E, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003; 124: 361-367.
39. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis 1998; 19: 49-53.
40. Jansson EA, Are A, Greicius G, et al. The Wnt/β-catenin signaling pathway targets PPARγ activity in colon cancer cells. Proc Natl Acad Sci USA 2005; 102: 1460-1465.
41. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 1998; 4: 1058-1061.
42. Matthiessen MW, Pedersen G, Albrektsen T, Adamsen S, Fleckner J, Brynskov J. Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand J Gastroenterol 2005; 40: 198-205.
43. Bogazzi F, Ultimieri F, Raggi F, et al. Peroxisome proliferator activated receptor γ expression is reduced in the colonic mucosa of acromegalic patients. J Clin Endocrinol Metab 2002; 87: 2403-2406.
44. Bogazzi F, Ultimieri F, Raggi F, et al. Changes in the expression of the peroxisome proliferator-activated receptor γ gene in the colonic polyps and colonic mucosa of acromegalic patients. J Clin Endocrinol Metab 2003; 88: 3938-3942.
45. Hollingshead HE, Borland MG, Billin AN, Willson TM, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis 2008; 29: 169-176.
46. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med 2004; 10: 481-483.
47. Marin HE, Peraza MA, Billin AN, et al. Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) inhibits colon carcinogenesis. Cancer Res 2006; 66: 4394-4401.
48. Wang D, Wang H, Guo Y, et al. Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression. Proc Natl Acad Sci USA 2006; 103: 19069-19074.
49. Zuo X, Peng Z, Moussalli MJ, et al. Targeted genetic disruption of peroxisome proliferator-activated receptor-δ and colonic tumorigenesis. J Natl Cancer Inst 2009; 101: 762-767.
50. Yang L, Zhou ZG, Zheng XL, et al. RNA interference against peroxisome proliferator-activated receptor δ gene promotes proliferation of human colorectal cancer cells. Dis Colon Rectum 2008; 51: 318-328.
51. Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 2001; 98: 2598-2603.